Department of Bacteriology and Immunology, Medicum, Research Programs Unit, Immunobiology Research Program, University of Helsinki, Helsinki 00290, Finland.
Division of Clinical Microbiology, HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki 00290, Finland.
Viruses. 2017 Sep 14;9(9):258. doi: 10.3390/v9090258.
is a commensal and pathogenic bacterium that causes infections in humans and animals. It is a major cause of nosocomial infections worldwide. Due to increasing prevalence of multidrug resistance, alternative methods to eradicate the pathogen are necessary. In this respect, polyvalent staphylococcal myoviruses have been demonstrated to be excellent candidates for phage therapy. Here we present the characterization of the bacteriophage vB_SauM-fRuSau02 (fRuSau02) that was isolated from a commercial bacteriophage cocktail produced by Microgen (Moscow, Russia). The genomic analysis revealed that fRuSau02 is very closely related to the phage MSA6, and possesses a large genome (148,464 bp), with typical modular organization and a low G+C (30.22%) content. It can therefore be classified as a new virus among the genus . The genome contains 236 predicted genes, 4 of which were interrupted by insertion sequences. Altogether, 78 different structural and virion-associated proteins were identified from purified phage particles by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The host range of fRuSau02 was tested with 135 strains, including 51 and 54 isolates from humans and pigs, respectively, and 30 coagulase-negative strains of human origin. All clinical strains were at least moderately sensitive to the phage, while only 39% of the pig strains were infected. Also, some strains of , , , , and were sensitive. We conclude that fRuSau02, a phage therapy agent in Russia, can serve as an alternative to antibiotic therapy against .
是一种共生和致病细菌，可引起人类和动物感染。它是全球医院感染的主要原因。由于多药耐药性的增加，需要寻找替代方法来消灭病原体。在这方面，多价葡萄球菌肌病毒已被证明是噬菌体治疗的优秀候选者。在这里，我们介绍了从俄罗斯 Microgen 公司生产的商业噬菌体混合物中分离出的噬菌体 vB_SauM-fRuSau02（fRuSau02）的特征。基因组分析表明，fRuSau02 与噬菌体 MSA6 非常密切相关，并且具有较大的基因组（148464bp），具有典型的模块化组织和较低的 G+C（30.22%）含量。因此，它可以归类为 属中的一种新病毒。基因组包含 236 个预测基因，其中 4 个被插入序列中断。总共通过液相色谱-串联质谱（LC-MS/MS）从纯化的噬菌体颗粒中鉴定出 78 种不同的结构和病毒相关蛋白。用 135 株菌测试了 fRuSau02 的宿主范围，包括 51 株和 54 株分别来自人和猪的 分离株，以及 30 株来自人类的凝固酶阴性 株。所有临床 株对噬菌体至少中度敏感，而只有 39%的猪株被感染。此外，一些 、 、 、 、 和 菌株也敏感。我们得出结论，fRuSau02 是俄罗斯的一种噬菌体治疗剂，可以替代抗生素治疗 。
